NEWS

Fibronostics and Fatty Liver Foundation Announce a Patient Education Partnership.

Fibronostic logo

The American Medical Association (AMA) and The Centers for Medicare & Medicaid Services (CMS) awarded LIVERFASt™ a CPT Code with the highest reimbursement fee in its category!

Name
Fibronostics

Fibronostics and Fatty Liver Foundation Announce a Patient Education Partnership

Dec 07, 2020
Fibronostics

Fibronostics US INC, receives CE (Conformité Européenne) mark approval for the product LIVERFASt™

Dec 01, 2020
Fibronostics

AASLD Poster: LIVERFASt is detecting and discriminant different phases of liver disease, with better performances than APRI or FIB-4.

Nov 25, 2020
Fibronostics

Fatty Liver Foundation featuring LIVERFASt™.

Nov 23, 2020
Fibronostics

AASLD Poster: Comparative performance of LIVERFASt™, Fibroscan and other non-invasive test for Severe Fibrosis in NAFLD Patients.

Nov 21, 2020
Fibronostics

Non-Invasive testing for NASH at the AASLD Liver Meeting.

Nov 09, 2020
Fibronostics

LIVERFASt™ provides the right diagnosis of liver disease conditions in type 2 diabetes patients.

Nov 01, 2020
Fibronostics

Fibronostics on its way to be a Healthcare Technology Powerhouse – Raises $8 Million Series A funding.

Aug 24, 2020
Fibronostics

Fibronostic’s Chief Scientific Officer,Dr Mona Munteanu, discussed relevance of Non-Invasive Testing for HCC Surveillance in global Webinar series.

Aug 21, 2020
Fibronostics

Sought-after Hepatology and Gastroenterology expert, Prof. Stephen A. Harrison MD joins Fibronostics’ Advisory Board.

Aug 05, 2020
Fibronostics

LIVERFASt screening and diagnostics capabilities combines with Health Catalyst National Registry power up a COVID19 study.

Jun 08, 2020
Fibronostics

Know the advantages of non-invasive liver diagnostics over standard biopsy as explained by our CEO, Roni Amiel.

Aug 21, 2020
Fibronostics

Celebrating a major milestone! Fibronostics granted CPT code for LIVERFASt, our non-invasive liver diagnostics tool.

Aug 05, 2020
Fibronostics

When things go tough due to flight restrictions, we conduct our CMEs through video conferences by our Chief Medical Officer, Dr Ronald Quiambao.

Jun 08, 2020
Fibronostics

Fibronostics presented a Scientific poster “Assessment of fatty liver disease using a biomarker-based non-invasive algorithm LIVERFASt™ test in South-East Asia”.at the NASH-TAG 2020, UTAH for.

Aug 21, 2020
Name
Fibronostics

AC Health announces Investment in Fibronostics by launching LIVERFASt and HealthFACTR in its FamilyDOC Clinics.

Jul 06, 2019
Fibronostics

Fibronostics presented our corporate strategy to current & potential investors in TKS 1 Investor Day in Singapore.

Feb 27, 2019
Fibronostics

Fibronostics mingles with industry leaders during inspiring few days at the American Association for the Study of Liver Diseases (AASLD) #LiverMtg19.

Nov 07, 2019
Fibronostics

Fibronostics is proud to partner with the CXA Group offering health and wellness screenings with HealthFACTR.

Dec 13, 2019